Thrombospondin-1 Signaling Mechanisms Regulating Pigment Epithelium-Derived Factor Expression and Lipolytic Activity in Prostate Cancer by Khamjan, Nizar
University of Wisconsin Milwaukee
UWM Digital Commons
Theses and Dissertations
August 2014
Thrombospondin-1 Signaling Mechanisms
Regulating Pigment Epithelium-Derived Factor
Expression and Lipolytic Activity in Prostate
Cancer
Nizar Khamjan
University of Wisconsin-Milwaukee
Follow this and additional works at: https://dc.uwm.edu/etd
Part of the Oncology Commons, and the Pathology Commons
This Thesis is brought to you for free and open access by UWM Digital Commons. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of UWM Digital Commons. For more information, please contact open-access@uwm.edu.
Recommended Citation
Khamjan, Nizar, "Thrombospondin-1 Signaling Mechanisms Regulating Pigment Epithelium-Derived Factor Expression and Lipolytic
Activity in Prostate Cancer" (2014). Theses and Dissertations. 702.
https://dc.uwm.edu/etd/702
THROMBOSPONDIN-1 SIGNALING MECHANISMS REGULATING 
PIGMENT EPITHELIUM-DERIVED FACTOR EXPRESSION AND 
LIPOLYTIC ACTIVITY IN PROSTATE CANCER 
 
 
by 
Nizar Khamjan 
 
 
A Thesis Submitted in 
Partial Fulfillment of the 
Requirements for the Degree of 
 
Master of Science 
in Biomedical Sciences 
 
 
at 
The University of Wisconsin-Milwaukee 
August 2014 
 
 
 
 
  
ii  
ABSTRACT 
 
THROMBOSPONDIN-1 SIGNALING MECHANISMS REGULATING 
PIGMENT EPITHELIUM-DERIVED FACTOR EXPRESSION AND 
LIPOLYTIC ACTIVITY IN PROSTATE CANCER 
 
 
By 
 
Nizar Khamjan 
 
The University of Wisconsin-Milwaukee, 2014 
Under the Supervision of Jennifer A. Doll, PhD 
 
 
 
 
Background: Prostate cancer (PCa) is the most common cancer that occurs in 
men in the United States. To grow, tumors need to induce new blood vessels growth, 
a process called angiogenesis. Thus, tumors down regulate molecules that inhibit this 
process. Two such molecules that are down-regulated in PCa are thrombospondin-1 
(TSP-1) and pigment epithelium-derived factor (PEDF). Interestingly, both of these 
proteins also function in regulating lipid metabolism. Our lab has data to suggest that 
TSP-1 induces PEDF expression and lipid catabolism (lipolysis), the hydrolysis of 
triglycerides into fatty acids and a glycerol, in PCa cells; however, the molecular 
pathway of this regulation has not been elucidated. Previous studies in PCa cells have 
also shown that TSP-1 treatment increases the levels of activated signaling mediators, 
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JNK and Src kinase. However, it is unclear if induction of JNK or Src is necessary for 
TSP-1- induced PEDF expression and/or lipolytic activity. In this study, I tested the 
hypothesis that Src and/or JNK signaling is required for TSP-1- induced PEDF 
expression and lipolytic activity in PCa cells.  
Methods: PCa cell lines, PC-3 (androgen insensitive) and LNCaP (androgen 
sensitive), and the normal prostate epithelial cell line, RWPE-1, were used in these 
studies. Cells were treated for 48 h with TSP-1 (5 or 20 nM) with or without chemical 
inhibitor treatment, either a JNK [SP600125] or Src family kinase [PP2] inhibitor (20 
μM). After 48 h, conditioned media (CM) and cell lysate (CL) samples were collected. 
CM was used to evaluate lipolysis activity via the free glycerol assay. PEDF levels were 
quanitified in both CM and CL by enzyme linked immunosorbent assay (ELISA) and 
Western blot analysis.  
Results: In RWPE-1, LNCaP, and PC-3 cells, no significant difference was 
observed in cell proliferation in response to TSP-1 or to either the JNK or Src inhibitor. 
Viability was decreased in response to TSP-1 in the presence of JNK inhibitor or Src 
inhibitor in LNCaP cells; whereas, in PC-3 cells, there was a slight increase in viability 
with TSP-1 in the presence of the JNK inhibitor treatment (P-value <0.010). In RWPE-
1 cells, both JNK inhibition and Src inhibition decreased lipolytic activity. Likewise, in 
the PCa cell lines, lipolytic activity was significantly decreased with either JNK or Src 
inhibitor treatment as compared to untreated cells (P-value <0.001). In LNCaP cells, 
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PEDF expression levels were significantly increased with TSP-1 at 5 nM with either 
JNK or Src inhibitor treatment. However in RWPE-1 CL, PEDF expression was 
decreased with TSP-1 at 5 nM in the presence of JNK inhibitor treatment.  
Conclusion: My data support that TSP-1- induced lipolytic activity is based on 
the activity of JNK and/or Src family kinase in RWPE-1 cells. The activation of JNK 
and/or Src family kinase could regulate PEDF expression in RWEP-1 and LNCaP cells. 
This study suggests that the JNK and/or Src kinase pathways could be a clinically 
relevant therapeutic target in PCa.  
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INTRODUCTION 
Prostate cancer  
 The prostate gland is a part of the male reproductive system. It is a 
walnut-sized gland located underneath the urinary bladder and in front of the 
rectum. The main function of the prostate is to secrete fluid that protects and 
nourishes sperm cells in semen [1]. The prostate gland is composed of four 
regions: the peripheral zone, central zone, and transition zone, and the anterior 
fibromuscular stroma [2, 3]. Diseases of the prostate gland include prostatitis, 
benign prostatic hyperplasia and prostate cancer (PCa), all of which have similar 
symptoms. The main manifestation of PCa is enlargement of the prostate gland 
which presses on the urethra. This pressure leads to blockage of urine flow and 
causes symptoms such as poor urine stream, urine retention, back pain, and 
hematuria [4].  
 
PCa is an extremely heterogeneous disease, but it is most often an 
adenocarcinoma or glandular cancer [5]. Approximately 95% of PCa are 
adenocarcinomas; 70% of these are localized in the peripheral zone, 15-20% in 
the central zone, and 10-15% in the transition zone [2, 6]. In metastatic PCa, 
tumor cells have the ability to migrate via the lymphatic system and the 
bloodstream to other organs, especially to the bone and brain [2]. PCa is the 
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second leading cause of cancer-related death after lung cancer in men in the 
United States [2]. According to the National Cancer Institute, in the United 
States, the number of men who will be diagnosed with PCa in 2014 is 
approximately 233,000. The estimated number of deaths from PCa is estimated 
at 29,480 [7]. Even though much progress has been made in understanding PCa, 
the main causes still remain unclear.  
 
 Several factors are believed to be major contributors to PCa development. 
They include genetic polymorphisms and mutations, increasing age, ethnicity, 
diet, and obesity [8]. Aging is one of the most significant risk factors increasing 
the chance of PCa [9], and most cases of PCa occur in older men, over the age 
of 65 [7]. Many studies have reported that PCa occurs more commonly in men of 
African and Caribbean descent and less often in other races [10]. This is likely 
connected to genetic polymorphisms.  
 
In cancer cells, critical genes are mutated or their expression is altered, 
leading to the cells being abnormal [11]. There are different factors that induce 
cancer progression, including sustained pro-proliferative signaling, evasion of 
growth suppressors, apoptosis resistance, replicative immortality, sustained 
angiogenesis, and tissue invasion and metastasis [12]. Angiogenesis is the 
growth of new vessels from the existing blood vessels. Tumors need a blood 
supply to sustain progressive growth, and by inducing angiogenesis the tumor 
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can grow larger [13]. Oncogenes and tumor suppressor genes are the main two 
types of genes that regulate these processes. Oncogenes play a causative role in 
transforming a normal cell to a tumor cell [14]; however, tumor suppressor 
genes protect and prevent healthy cells from becoming cancerous [15]. When a 
tumor suppressor gene and/or an oncogene is mutated or altered, this can 
promote tumor growth. 
  
 In addition, another possible risk factor for PCa is a diet that contains red 
meat and/or is high in fat and/or low in fruits and vegetables [9]. Lastly, obesity 
is a major risk factor that is associated with disease progression, rather than 
incidence of disease. Furthermore, obese men who consume milk, cheese, eggs, 
and meat show a significantly higher risk of lethal PCa compared to lean men 
[16]. Some general population studies have shown that obesity is highly 
associated with high-grade PCa at diagnosis [16].  
 
Diagnosis, classification and treatment of PCa 
 The early stages of PCa often cause minimal or no symptoms. In more 
advanced stages, symptoms are present, and the PCa can be aggressive. There 
are three different diagnostic tests that are widely used in conjunction to identify 
and diagnose PCa. These three tests are the prostate specific antigen (PSA) 
blood test, the digital rectal examination (DRE), and transrectal ultrasound-
guided biopsy (TRUS). The first two are routinely used to screen for PCa, but a 
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biopsy with histologic examination is necessary to firmly establish a diagnosis of 
PCa. In DRE, the prostate gland is physically examined to estimate the size of 
the prostate gland. An elevated PSA level may indicate the presence of PCa; 
however, the test is not specific, as other diseases of the prostate also elevate 
PSA. If either the DRE or PSA indicates the possible presence of PCa, a TRUS is 
used to guide needle biopsies.  
 
  Based on histological examination of prostate tissue, as well as other 
imaging techniques, PCa is divided into different stages and grades. To 
determine the stage of PCa, the TNM (tumor, node, and metastasis) system is 
used [17]. Each category has subdivisions to allow precise staging of the cancer. 
“T” is used to evaluate how much of the prostate is tumorous and also to 
indicate if the tumor has extended through the prostate capsule and invaded into 
other nearby structures. The “N” indicates if PCa has migrated to surrounding 
lymph nodes (proximal lymph nodes). “M” describes if the PCa has metastasized 
to other parts of the body [17]. The histological grading system for PCa is the 
Gleason score, which is based on histological examination of prostate tissue 
stained with hematoxylin and eosin [18]. According to the appearance of the 
glands and cells in the prostate tissue, a grade of 1 – 5 will be assigned [18]. 
The most prominent pattern and the second most common pattern are added to 
give a Gleason score of 2-10 [18]. A score that is 6 or over is considered PCa, 
and cancers that are scored 7 and above indicates a clinically aggressive cancer. 
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Additional tests, such as magnetic resonance imaging, computerized tomography 
scans, and bone scans, may be recommended to identify the stage of cancer 
progression [19].  
 
 If a diagnosis of PCa is confirmed, treatment options are based on the 
stage and grade of the cancer [18]. If PCa is diagnosed at an early stage, 
effective treatments are available for patients. These options include surgery 
(radical prostatectomy), radiotherapy, hormone treatment, immunotherapy 
treatment, and chemotherapy. In some cases, these treatments are combined 
together to improve outcomes. However, each treatment can have serious side 
effects for patients [20]. It is believed that anti-angiogenesis treatments may be 
effective in treating PCa. Specifically, several novel therapies targeting vascular 
endothelial growth factor (VEGF), a potent pro-angiogenic factor, and its 
receptors have improved survival in advanced PCa [21]. Thus, anti-angiogenic 
drugs are a promising therapy to stop tumor growth. 
 
PCa progression and angiogenesis 
 Angiogenesis, which is regulated by multiple proteins, can be activated by 
the presence of pro-angiogenic factors such as VEGF, platelet derived growth 
factor, basic fibroblast growth factor, and interleukin-8 (IL-8) [13, 22]. On the 
other hand, angiogenesis can be inhibited by the presence of anti-angiogenic 
proteins such as pigment endothelium-derived factor (PEDF) and 
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thrombospondin-1 (TSP-1) [23, 24]. It is ultimately the balance of pro- and anti-
angiogenic factors that determines angiogenic activity. The mechanism of 
production of pro- and anti-angiogenic factors is regulated in normal cells, and 
the levels of angiogenesis inhibitor proteins are higher than that of inducer 
proteins. However, in tumors, pro-angiogenic protein levels are increased over 
that of anti-angiogenic proteins, resulting in induction of angiogenesis, which 
allows tumor progression. Both TSP-1 and PEDF expression levels are decreased 
or lost in PCa [25, 26].  
 
Pigment epithelium-derived factor (PEDF) in PCa 
 PEDF is a 50 kDa multifunctional glycoprotein [27]. Several functions of 
PEDF are now recognized: a potent inhibitor of angiogenesis, neuroprotection, 
and an inducer of cell differentiation [28]. PEDF was originally isolated from 
retinal pigment epithelial cell secretions [27] and belongs to the serine protease 
inhibitors (serpins) family [27]. The serpins family is composed of two distinctive 
groups. The structure of these two groups is similar, but one group has a region 
called the reactive center loop. This region interacts with the specific protease 
target, but the other group does not have this active region [29]. The first group 
plays a fundamental role in inflammation, blood coagulation, and extracellular 
matrix reconstitution [27], while the second group functions in such processes as 
hormone transport, molecular chaperones, and tumor suppression [29].  
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PEDF is broadly expressed throughout the body [28], and its function as a 
potent inhibitor of angiogenesis has been well studied in cancer, and as such, 
functions as a tumor suppressor. Importantly, lower PEDF levels in cancer tissues 
correlate with metastasis and poor prognosis in several cancer types, including 
PCa, pancreatic cancer, hepatic carcinoma and neuroblastoma [30-32]. 
Emphasizing PEDF’s function as a tumor suppressor gene in the prostate, PEDF-
deficient mice develop prostate epithelial hyperplasia and increased prostate 
stromal microvessel density compared to wildtype mice [25]. In addition, the 
treatment of PCa tumor xenografts with recombinant PEDF decreased stromal 
vasculature and induced apoptosis [25]. PEDF is also down regulated by 
androgens in PCa cells [25]. Another study has shown that in human hormone-
refractory PCa cells, PEDF inhibits the secretion of IL-8, which is a key effector in 
the progression of PCa [33].  
 
PEDF in lipid metabolism 
In addition to its role as a tumor suppressor, PEDF also has been 
implicated in regulating lipid metabolism [34]. Lipids play several biological roles, 
such as energy storage, forming cell membranes, and hormonal regulation [35]. 
It is believed that alterations in lipid metabolism in cancer cells occur during 
malignant transformation [36], which may contribute to features of solid tumors, 
such as growth, proliferation, and invasion [37]. PEDF is also an adipocyte-
secreted factor [34]. While some studies report that PEDF is associated with the 
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development of obesity-related insulin resistance, increasing adipocyte lipolysis, 
and promoting lipid accumulation in muscle and liver [38, 39], other studies 
show that PEDF is increased in response to insulin resistance [39]. PEDF is 
reported to bind to adipose triglyceride lipase (ATGL), which catalyzes the initial 
step in triglyceride hydrolysis [40]. The main function of ATGL is to remove the 
first fatty acid from the triglyceride molecule, generating a free fatty acid and a 
diacylglycerol [41]. With ATGL deficiency in mice, there was increased fat 
depositions and triglyceride accumulation in nearly every organ [40]. Moreover, 
PEDF-deficient mice have altered liver lipid metabolism, resulting in hepatic 
steatosis [42]. Another study in retinal epithelial cells identified that ATGL is a 
cell surface receptor for PEDF [43]. Other studies have shown that recombinant 
PEDF co-localizes with ATGL on lipid droplets in hepatocytes and in adipose 
tissues [42]. PEDF-ATGL interaction was further confirmed by co-
immunoprecipitation studies in hepatocyte and human hepatocellular carcinoma 
cell lines [42]. In an ATGL- deficient mouse model, PEDF induces adipocyte 
lipolysis and triacylglycerol lipase activity in skeletal muscle and liver in ATGL-
dependent manner [44]. Taken together, these results indicate that PEDF is 
involved in lipid metabolism; however, neither this function nor the molecular 
pathway has been examined in the prostate.  
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Thrombospondin-1 (TSP-1) in PCa  
 The thrombospondin (TSP) family of proteins consists of five 
multifunctional proteins that interact with a variety of molecules, such as heparin 
and fibrinogen [45, 46]. Of this family, TSP-1 has been studied intensively. TSP-1 
is a large, 420 kDa, homotrimeric molecule and is a matricellular glycoprotein 
secreted from a variety of normal cells, such as endothelial cells, epithelial cells, 
fibroblasts, macrophages, and adipocytes [47]. TSP-1 is the only member of the 
TSP family that has the ability to activate latent transforming growth factor-beta 
1 (TGF-β1) [48]. TSP-1 also has an N-terminal globular domain that has the 
ability to interact with a variety of protein receptors, such as CD36 and CD47 
[49]. TSP-1 binding to CD47 induces apoptosis of B-cell chronic lymphocytic 
leukemia [50] and is responsible for the migratory response of smooth muscle 
cells [51]. CD36, also known as fatty acid translocase, is a glycosylated protein 
member of the class B scavenger receptors [52]. CD36 also has several essential 
functions in fatty acid and glucose metabolism [53]. The interaction between 
TSP-1 and CD36 is important to activate anti-angiogenesis and inflammation 
[54]. The interaction between TSP-1 and CD36 induces apoptosis of endothelial 
cells [55]. 
 
TSP-1 has been identified as a functional inhibitor of angiogenesis in 
normal prostate epithelial cells [26]. Decreased levels of TSP-1 have been 
reported in PCa cells [26]. These decreased levels, combined with the increased 
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level of angiogenesis inducers such as vascular endothelial growth factor and 
fibroblast growth factor in PCa tissue, lead to tumor progression [26]. Some 
studies have revealed that the regulation of prostate growth is, at least in part, 
dependent upon TSP-1’s activation of TGF-β1, which inhibits prostate epithelial 
cell proliferation [24]. In TSP-1-deficient mice, microvessel density and epithelial 
proliferation were increased in the prostate tissue [24]. In the human PCa cell 
line, LNCaP, the expression level of TSP-1 is decreased in comparison with the 
PNT 1A cell line, an SV40-immortalized normal human prostate epithelial cell 
[26].  
 
As stated above, TSP-1 is a matricellular protein secreted from adipose 
tissue. In several organs, including the kidney, the heart, and adipose tissue, 
TSP-1 expression levels are increased in animal models of obesity and diabetes 
[56-59]; however, the role of this increase is not currently understood. Moreover, 
several studies show that TSP-1 is highly expressed in diabetic and obese 
patients [59]. Adipose TSP-1 expression has been associated with metabolic 
dysfunction in obese patients [60]. In previous studies in prostate cells, TSP-1 
treatment increased lipolytic activity (Doll et al., unpublished data). However, 
TSP-1 treated PC-3 cell lines exhibited variable effects on lipolytic activity (Doll et 
al., unpublished data).  
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 Several reported studies have assessed the correlation between TSP1 and 
PEDF levels in disease models. In human malignant U251 glioma cells, increased 
PEDF expression regulates TSP-1 [61]. Another study shows that PEDF treatment 
increases TSP-1 levels, so that led to decrease human KM12 colon cancer 
microvessel density, and their expression increased macrophage recruitment 
[62]. Similarly, other groups show that PEDF and TSP-1 have induced 
macrophage recruitment into PCa and human melanoma tumors, with increased 
tumor cell apoptosis [63, 64]. The effects of TSP-1 on PEDF expression in PCa 
have been examined in several tissue types, as well. TSP-1 treatment increases 
secreted PEDF levels in RWPE-1, PC-3, DU145, and LNCaP cells (Doll et al., 
unpublished data). However, intracellular levels of PEDF were increased in LNCaP 
and PC-3 cells, but decreased in RWPE-1 and DU145 cells, with TSP-1 treatment 
(Doll et al., unpublished data). In addition, TSP-1 treatment also increased 
lipolytic activity in PCa cells (Doll et al., unpublished observation). The molecular 
pathways through which TSP-1 regulates PEDF expression and lipolytic activity in 
prostate cells is currently uninvestigated. 
 
Signaling mediators, JNK and Fyn, in PCa 
Previous studies demonstrated that TSP-1, via signaling molecules c-Jun 
N-terminal kinase (JNK) and Fyn promotes cell death in endothelial cells [54]. 
Decreased endothelial cell proliferation and migration in vitro have been reported 
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after JNK inhibition. Thus, JNK plays a prominent role in regulation of angiogenic 
activity in endothelial cells [65]. TSP-1, furthermore, is unable to inhibit 
angiogenesis in the cornea of Fyn null mice [66]. Even though there are many 
publications describing the effects of various mitogen-activated protein kinase 
(MAPK) pathways in cancer in general [67], the function of the MAPK pathways 
in PCa are not clearly understood. Moreover, while the TSP-1 signaling cascade is 
well established in endothelial cells [54], little is known about its signaling 
pathways in PCa cells. In preliminary work, TSP-1 treatment induced the 
expression levels of JNK and Fyn in PCa cells (Doll et al., unpublished data); 
therefore, in these studies, I investigated if these signaling molecules are 
necessary for induction of PEDF expression and lipolytic activity in response to 
TSP-1 treatment. In the PC-3 cell lines, TSP-1 treatment led to increased 
expression of JNK and Fyn kinases (Doll et al., unpublished data).  
 
JNKs belong to a group of serine/threonine protein kinases known as 
MAPKs. There are three mammalian genes encoding the JNK family: JNK1, JNK2, 
and JNK3 [68]. A role for JNKs is well established in proliferation, survival and 
differentiation of many cell types. The JNK pathway can be activated by 
ultraviolet radiation [69], cytokines, environmental stresses, and growth factors 
[70]. JNK expression levels are increased in different types of cancer, such as 
prostate, breast, lung, and pancreatic [71]. A number of findings show that JNK 
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expression in PCa is increased in comparison with normal or benign hyperplasia 
epithelium tissue [72]. Some studies show that JNK may induce PCa metastasis 
through its ability to regulate cell adhesion, invasion, and migration [73]. In a 
mouse model of PCa, JNK is increased expression in PCa cells and induces 
prostate tumorigenicity [74]. On the other hand, chemical inhibition of JNK 
decreases the activity of cell migration in DU145 PCa cells [73]. Moreover, it has 
been shown that the activation of JNK signaling pathway is necessary for 
regulation of cell death in PC-3 cells [75].  
 
 Fyn is a member of the Src family of tyrosine protein kinases [76]. Fyn is 
a 59-kDa protein that functions in the signaling pathway of integrins, which 
activates the Ras pathway, leading to activation of the MAPK cascade [77]. The 
biological functions of Fyn are diverse, including cell adhesion, proliferation, ion 
channel function, and integrin-mediated signaling [77]. Fyn interacts with the 
cytoplasmic regions of a broad range of surface molecule, such as CD36 and 
CD44 [78]. In PCa, Fyn is upregulated during cancer progression [79]. It has 
been indicated that the levels of Fyn and its signaling mediators are increased in 
LNCaP and PC-3 cell lines [79].  
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HYPOTHESIS AND SPECIFIC AIMS 
 
 PCa is the second leading cause of cancer-related death in men in the United 
States [7]. The progression of PCa depends on inducing the formation of new blood 
vessels, a process called angiogenesis. TSP-1 and PEDF are both anti- angiogenic 
proteins, and their expression is down-regulated during PCa progression [25]. Both of 
these proteins are multifunctional, and both appear to function in lipid metabolism 
[42]. Our lab has data to suggest that TSP-1 treatment in PCa cells induces PEDF 
expression and lipolytic activity (Doll et al., unpublished data), though little is known 
about the signaling pathway mediating this activity. In other cell types, such as 
endothelial cells, TSP-1 inhibits endothelial cell proliferation through activation of the 
signaling molecules JNK and Fyn [54]. In some PCa cell lines, TSP-1 treatment 
increased the expression level of JNK and Fyn (Doll et al., unpublished data). 
However, the molecular pathways mediating TSP-1- induced PEDF expression and 
lipolytic activity in regulation of PCa cells have not been elucidated, and further 
exploration is needed. It is also unclear if induction of JNK or Fyn is necessary for 
TSP-1- induced PEDF expression and lipolytic activity. This study examined whether 
TSP-1 induction of Fyn or JNK signaling is required for TSP-1- induced PEDF 
expression and lipolytic activity in PCa. The central hypothesis of this study was that 
TSP-1- induced PEDF expression and lipolytic activity is dependent on 
induction of JNK and/or Fyn signaling in RWPE-1 normal prostate epithelial 
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cells and in the PCa cells, LNCaP and PC-3. To examine this hypothesis, I 
proposed the following specific aims: 
Specific Aim 1: Determine if JNK or Fyn signaling is necessary for TSP-1 
induced PEDF expression in prostate cells. My working hypothesis for aim 1 
was that TSP-1 treatment decreases PEDF expression through JNK and/or Fyn 
kinase signaling pathways in prostate cell lines. I tested this hypothesis by:  
a) Treating cells with TSP-1 with or without a chemical inhibitor of JNK or Fyn 
and; 
b) Measuring PEDF expression levels in both the conditioned media and cell 
lysates. 
Specific Aim 2: Determine if JNK or Fyn signaling is necessary for TSP-1 
induced lipolytic activity in prostate cells. My working hypothesis for aim 2 
was that blocking JNK and Fyn signaling in PCa cells during TSP-1 treatment 
inhibits lipolytic activity. I tested this hypothesis by: 
a) Collecting an aliquot of conditioned media from cells treated in Aim 1a and;  
b) Quantifying lipolytic activity in these samples. 
 
The main objective of this study is to identify the molecular pathway of the 
effects of TSP-1 treatment on PEDF expression and lipolytic activity in prostate 
cells. Analyzing the molecular pathways and identifying the mediators of TSP-1 
activity in PCa cells may serve as candidates for future therapeutic targets for 
PCa treatment. 
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MATERIALS AND METHODS 
Cell lines 
  In this study, three cell lines were used, RWPE-1, LNCAP and PC-3 cells. 
RWPE-1 cells are an immortalized normal adult human prostatic epithelial cell 
line from a white male donor, and they were immortalized by transfection with 
human papillomavirus 18 [80]. PC-3 cells were established from a human 
prostatic adenocarcinoma metastasis to bone [81], and LNCaP is a PCa cell line 
derived from a lymph node metastasis of a human PCa [82].  
 
Culture and treatment of cells 
RWPE-1 cells were grown in keratinocyte complete media (Gibco, Grand 
Island, NY, Cat. No. 10724-011) with 1% penicillin / streptomycin (P/S, Cellgro, 
Manassas, VA, Cat. No. 30-002-CI). PC-3 cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Sigma, St. Louis, MO, Cat. No. D5796) with 10% fetal 
bovine serum (FBS, Sigma, St. Louis, MO, Cat. No. F2442), and 1% P/S. The 
LNCaP cell line was grown in Roswell Park Memorial Institute (RPMI) media 
(Sigma, St. Louis, MO, Cat. No. R8758) with 10% FBS and 1% P/S. All cells were 
incubated at 37°C in 5% CO2 for propagation. 
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 Cells were cultured to obtain five confluent plates of cells. On day 1 of the 
experiment, confluent plates of cells were harvested by trypsinization. An aliquot 
was taken from the trypsinized cells for counting, and cells were centrifuged at 
800 x g for eight minutes. The supernatant was aspirated off the cell pellet and 
discarded. The cell pellet was resuspended in a volume of media to achieve a cell 
density of 20,000 cells/cm2 for RWPE-1 and PC-3 cells, and 40,000 cells/cm2 for 
LNCaP cells. All cells were plated into 10 cm tissue culture dishes. Therefore, ten 
dishes were plated for each cell line, as there were 10 treatment groups (Table 
1). Each cell line was grown with its own specific growth medium and incubated 
overnight for cell attachment. On day 2, the growth media was aspirated off, and 
cells were gently rinsed one time in 5 ml of phosphate buffered saline (PBS, 
Cellgro, Manassas, VA, Cat. No. 21-031-CV). Serum-free basal media, containing 
only P/S, was then added, and the cells were incubated for 4 h. This 4 h 
incubation was to synchronize cells in the cell cycle. During the four hour 
incubation, treatment medias were prepared in basal media plus 1% P/S only, as 
described in Table 1. TSP-1 treatments (R&D Systems inc, Minneapolis, MN, Cat. 
No. 3074-TH) were prepared at 5 or 20 nM, as indicated in Table 1. For the JNK 
inhibition SP600125 (CALBIOCHEM, Billerica, MA, Cat. No. 420119) was used at 
20 µM (Table 1). For Fyn inhibition, a specific inhibitor was not available; 
therefore, I used the src family kinase inhibitor PP2 (CALBIOCHEM, Billerica, MA, 
Cat. No. 529573) at 20 µM (Table 1). After the 4 hour incubation, the basal 
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media were aspirated and the treatment medias were gently added. Cells were 
then incubated for 48 hours. 
 
 
 
Table 1. Treatment groups. 
Treatment groups TSP-1 (nM) 
SP600125 
(µM)  
PP2  
(µM)       
DMSO 
 (µl) 
 1. Untreated (negative control) 0 0 0 0 
 2. TSP-1  5 0 0 0 
 3. TSP-1 20 0 0 0 
 4. SP600125 (JNK) 0 20 0 0 
 5. TSP-1 + SP600125 5 20 0 0 
 6. TSP-1 + SP600125 20 20 0 0 
 7. PP2 (Src, Fyn) 0 0 20 0 
 8. TSP-1 + PP2  5 0 20 0 
 9. TSP-1 + PP2 20 0 20 0 
 10. DMSO* 0 0 0 5.1 
 
*DMSO; equal to the largest volume.  
 
Collection of conditioned media  
 After 48 hours of incubation, the serum-free conditioned media (CM) were 
collected by treatment group. The CM was then centrifuged at 800 x g for eight 
minutes at 4ºC to pellet any cells and/or cellular debris. After centrifuging, the 
CM was transferred to a new conical tube. Aliquots were then taken for the 
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lipolysis assay, after which protease inhibitors were added to the remaining CM 
[1X protease inhibitor cocktail (Sigma, St. Louis, MO, Cat. No. P8340) and 
phenylmethanesulfonyl fluoride (PMSF, 1 µM; Sigma, St. Louis, MO, Cat. No. 
93482)]. The samples stored at 4°C until further processing.  
 
Proliferation assay and viability 
 The treated cells were then trypsinized by adding 1 ml of trypsin reagent to 
each 10 cm dish (Cellgro, Manassas, VA, Cat. No. 25-053-CL). Trypsinization was 
stopped by adding 2 ml of growth media, containing serum. A 50 µl aliquot of 
this cell solution was added to an equal volume of 0.4% trypan blue stock 
solution (Sigma, St. Louis, MO, Cat. No. T8154). The trypsin/cell solution was 
incubated for five minutes at room temperature. I then counted total cells and 
live cells on the Cellometer (Cellometer Auto T4, Bioscience, Nexcelom, 
Lawrence, MA) per the manufacturer’s protocols. Briefly, 20 μl of the cell-trypan 
blue solution was taken and placed in a Cellometer slide chamber (Nexcelom, 
Lawrence, MA, Cat. No. SD100) in duplicate. The slide was read for total cell 
number and viable cell number on the Cellometer for each experimental group. 
Dead cells incorporated the dye and appeared blue. The living cells appeared 
colorless and bright. Average cell counts were calculated and used to normalize 
the lipolysis data. 
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Quantification of lipolytic activity 
 Lipolytic activity was determined indirectly by measuring free glycerol levels 
in the CM. When triglycerides are broken down during lipolysis, three free fatty 
acids and a glycerol molecule are generated, and the glycerol is secreted from 
cells. This glycerol can be detected based on an enzymatic reaction using the 
Free Glycerol Reagent, which produces a colored product that can be quantified 
by spectrophotometry (Sigma, St. Louis, MO, Cat. No. F6428). The blanks were 
prepared by adding glycerol reagent alone to a cuvette to adjust the absorbance 
to zero in a 1.5 mL disposable cuvette. The standards were prepared from the 
glycerol standard solution (Sigma, St. Louis, MO, Cat. No. G7793) and ranged in 
concentration from 0.26 to 0.0325 mg/ml.  
  
 A serial dilution of glycerol standard was assayed to generate a standard 
curve. For each of the CM samples, 200 μl of the CM was added to 800 μl of free 
glycerol reagent. The samples were analyzed on the spectrophotometer 
(Shimadzu, Kyoto, Tokyo, model No. UV-2501PC). The absorbance at 540 nm 
was obtained and the concentration based on the standard curve. From the cell 
count above, free glycerol levels were reported as levels per total cell number. 
Levels were then compared to untreated as fold-over values. 
 
21  
 
 
Cell lysate collection 
 To collect cell lysate (CL), 1X cell lysis buffer (Cell Signaling, Danvers, MA, 
Cat. No. 98035) was used with the addition of protease inhibitor cocktail (1X) 
and PMSF (final [1 μM]). Cells that were trypsinized above were centrifuged at 
800 x g for eight minutes after the aliquot was taken for the cell proliferation 
assays. The supernatant was aspirated and discarded. The cell pellet was 
resuspended in 350 µl of 1 x cell lysis buffer, and then the cell suspension was 
incubated on ice for five minutes. I then vortexed the cell mixture for twenty 
seconds. The CL solution was transferred to a microfuge tube and centrifuged at 
14,000 x g at 4°C for ten minutes to pellet the cellular debris. Next, the 
supernatant was collected into siliconized tubes. Samples were stored at -80°C 
until use.  
 
CM concentration 
For subsequent protein analysis, the CM was concentrated using a 
Millipore ultra-15 centrifugal filter device (Amicon Ultra Centrifugal Filters, 
Millipore, Billerka, MA, Cat. No. UFC900324). Using 5 ml of sterile PBS to wet the 
membrane device, I centrifuged the tube at 4000 x g for 10 minutes at 4°C. The 
PBS was removed, and then the 5 ml of CM were added and centrifuged at 4000 
x g for 30 minutes. Additional spins were performed until almost all of the media 
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had filtered. The CM was then washed with one to two volumes of PBS to 
remove the phenol red color. The CM were then concentrated 10 fold, which was 
approximately a 500 µl volume from 5 ml of CM. Finally, the concentrated CM 
was transferred to a sterile siliconized microfuge tube and stored it at -80°C until 
use. 
 
Protein quantification 
 A Coomassie (Bradford) protein assay was conducted for the quantification 
of total protein in both the CM and CL samples. In this colorimetric reaction, 
protein content of a sample is determined by comparison to the development of 
color in a set of standards that are used to generate a standard curve. The 
standard solution consisted of a series of known dilutions of bovine serum 
albumin (BSA, Thermo, Rockford, IL, Cat. No. 23208. The protocol of the 
Coomassie reagent (Thermo Scientific, Rockford, IL, Cat. No. 1856209) was 
followed per the manufacturer’s instructions. Briefly, 490 µl of Coomassie 
reagent were added to the tubes. Samples were prepared by adding 10 µl of 
standard solutions, 10 µl of CM, or 5 µl of CL in addition to 5 µl of PBS. Then, 
200 µl of each standard or samples were transferred into the appropriate well of 
a microplate in duplicate wells. The absorbance at 595 nm was measured on a 
plate reader (BioTek, Synergy HT). The KC4 program generated a standard curve 
and calculated the mean concentrations of each sample.   
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PEDF level detection 
  In this study, an enzyme-linked immunosorbent assay (ELISA) was 
employed to quantify the concentration of PEDF levels in both CM and CL 
samples. The manufacturer’s instructions (BioProducts MD, Middletown, MD, Cat. 
No. PED613) were followed. Briefly, all standards were prepared as a series of 
known dilutions. Then 100 µl of each CM and CL specimens, or PEDF standard 
solutions, were pipetted into duplicate wells. Two wells were left empty to serve 
as blanks. After adding all specimens and standards, the microplate was covered 
and incubated at 37°C for one hour. After aspirating the solution from the plate, 
I then washed each well of the microplate five times with 1x wash buffer to 
remove unbound antigen. Next, 100 µl of PEDF antibody was added to bind to 
the antigen. After that, the plate was covered and again incubated at 37°C for an 
hour.  
 
 The plate was washed five times to remove the unbound PEDF antibody. 
After washing, 100 µl of streptavidin peroxidase working solution was pipetted 
into each well to produce a detectable color in proportion to the PEDF bound in 
each well. The plate was incubated for 30 minutes at room temperature. After 
this incubation period, 100 µl of tetramethylbenzidine substrate solution was 
added to each well to produce a detectable color, and incubated uncovered at 
room temperature for 30 minutes. To stop the reaction, 100 µl of stop solution, 
which changes the color from blue to yellow, was pipetted in to each well. The 
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absorbance at 450 nm in each well was measured on a plate reader (BioTek, 
Synergy HT). PEDF concentrations were calculated based on the standard curve 
and compared to untreated sample levels as fold over untreated.  
 
Western blot assay 
 The Western blot assay was used to visualize and compare the PEDF in CL 
samples. CL samples were prepared with 2X Laemmeli sample buffer (BIO-RAD, 
Hercules, CA, Cat. No. 161-0737) in a total volume of 40 μl. Samples were then 
incubated at 95°C to ensure denaturation and then cell samples were separated 
by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis [SDS-PAGE; 
12% precast acrylamide gel (BIO-RAD, Hercules, CA, Cat. No. 456-1043)]. For a 
size standard, 10 μl of prestained protein marker (BIO-RAD, Hercules, CA, Cat. 
No. 161-0374) was used. Gels were run in Tris-glycine-SDS buffer (BIO-RAD, 
Hercules, CA, Cat. No. 161-0732) at 120 volts for approximately one and a half 
hours. After proteins were resolved sufficiently on the gels, electrophoresis was 
stopped, and I then washed the gels with transfer buffer (1X Tris-glycine and 
20% methanol) for 10 minutes.  
 
 The separated proteins were transferred from the gel, by electroblotting, to 
a polyvinylidene difluoride (PVDF) membrane (GenHunter Corporation, Nashville, 
TN, Cat. No. B301-50) at 50 volts for two hours. After the transfer of the 
proteins from the gels, the membranes were blocked, to prevent nonspecific 
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binding of the detection antibodies during subsequent steps, at room 
temperature for an hour. The blocking solution was prepared as follows: 1X Tris 
buffered saline (TBS, Sigma, St. Louis, MO, Cat. No. T5912) with 0.05% Tween-
20 (Sigma, St. Louis, MO, Cat. No. P2287), plus 5% dry milk. The 1X TBS-
Tween-20 (TBS-T, 50 ml) solution alone (no dry milk) was used to wash the 
membranes two times for 10 minutes each.  
 
 For PEDF detection, the membranes were hybridized with anti-PEDF 
antibody (Millipore, Temecula, CA, Cat. No. MAB1059) as the primary antibody. 
Primary antibody was diluted at 1:1000 in TBS-T and 5% dry milk and incubated 
at 4°C on a shaker overnight. The following day, membranes were washed three 
times with 50 ml of TBS-T for 10 minutes each. Secondary antibody, goat anti-
mouse IgG horseradish peroxidase (HRP) conjugate (Millipore, Temecula, CA, 
Cat. No. 12-349), was diluted at 1:2500 in TBS-T plus 5% dry milk. The 
membranes were then incubated with secondary antibody at room temperature 
for one hour. The membranes were then washed thrice with 50 ml of TBS-T for 
10 minutes each. The membranes were also washed with 50 ml of TBS for ten 
minutes. The PEDF were detected using a chemiluminescent detection system 
(Pierce Pico reagents, ThermoScientific, Rockford, IL, Cat. No. 34080) through 
enzymatic reaction with HRP. The blots were exposed to X-ray film 
(ThermoScientific, Rockford, IL, Cat. No. 34093) to obtain an autoradiogram for 
a permanent record.  
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 Probed membranes were stripped using boiling 1% SDS at room 
temperature for two hours. The stripped membranes were washed and blocked 
before re-probing. For a protein loading control, GAPDH expression was detected 
in the stripped membranes by conducting the same Western blot protocol as 
described above. Anti-GAPDH primary antibody was used (Cell Signaling, 
Danvers, MA, Cat. No. 3683S). Anti-rabbit IgG, HRP linked antibody (Cell 
Signaling, Danvers, MA, Cat. No. 7074S) was utilized as secondary antibody. 
 
Statistical Analysis 
 All the experiments were repeated at least twice. Data for each kinase 
inhibitor were graphed and analyzed separately; however, the controls used 
(untreated, TSP-1, and DMSO treatments) were the same. Student t-test and 
ANOVA analysis were performed to test if significant results were obtained in 
these experiments. ANOVA with Bonferroni post-hoc test was used to compare 
dose responsiveness. Student t-test was employed for pairwise comparisons 
where appropriate. PEDF levels and free glycerol levels in TSP-1 treated cells 
were compared to untreated cells and to TSP-1 with chemical inhibitors of JNK 
and Fyn. Differences between experimental groups were considered statistically 
significance if the P value was ≤ 0.05. 
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RESULTS 
The effects of TSP-1 treatment with or without kinase inhibitor 
treatment on the proliferation and viability of normal prostate 
epithelial cells and PCa cells 
 TSP-1 suppresses angiogenic activity both in in vivo and in vitro 
experiments and slows the growth of tumors by inhibiting angiogenesis [83]. In 
TSP-1-deficient mice, epithelial proliferation was increased in the prostate [24]. 
In endothelial cells, TSP-1 promotes cell death by activating signaling molecules 
JNK and Fyn [54]. To investigate whether Src or JNK signaling was necessary for 
TSP-1 signaling, I treated normal prostate epithelial cells (RWPE-1) and PCa cells 
(LNCaP and PC-3) with 5 or 20 nM TSP-1 in the presence or absence of a JNK 
inhibitor or a Src family kinase inhibitor (20 μM). The JNK pathway was inhibited 
using SP600125, a JNK1/2 specific inhibitor. A specific Fyn kinase inhibitor was 
not available; therefore, I used PP2, a chemical inhibitor of Src family kinases. I 
then assessed total cell numbers and viable cell numbers on a Cellometer.  
  
 As shown in Figure 1A, no significant differences were observed in RWPE-1 
cell proliferation between groups. Likewise, no differences in proliferation were 
observed in the PCa cells, PC-3 and LNCaP (Figure 1B and 1C). With regards to 
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cell viability, no significant difference was observed between groups in RWPE-1 
cells (Figure 2A). As shown in Figure 2B, in PC-3 cells, the only treatment group 
that had a slight, but significant, effect on cell viability was the TSP-1 (5 nM) 
with JNK inhibitor, SP600125, treatment as compared to either TSP-1 at 5 nM 
alone (P-value <0.010) or JNK inhibitor alone (P <0.044). In LNCaP cells, a 
decrease in cell viability was observed with TSP-1, 20 nM with JNK inhibitor, 
SP600125, treatment compared to TSP-1, 20nM alone (P-value <0.012), but not 
as compared to JNK inhibitor alone (Figure 2C). No other differences in viability 
were observed in these cells.  
 
Figure 1. TSP-1 treatment and JNK inhibitor, SP600125, treatment do not 
affect proliferation of RWPE-1, PC-3 or LNCaP cells. Both RWPE-1 (A) and PC-3 
(B) were plated at 20,000 cells/cm2, and LNCaP cells (C) were plated at 40,000 
cells/cm2 in tissue culture dishes. All cells were incubated overnight. Cells were treated 
with TSP-1 with or without a chemical inhibitor of JNK (SP600125) and incubated for 48 
hours. Cells were collected by trypsinization, and total cell numbers were counted on a 
Cellometer. Data were presented as fold over the untreated control group. DMSO was 
the solvent for the JNK inhibitor. Controls were the untreated cells, TSP-1, and DMSO 
treatments. The experiment was repeated at least twice with similar results. 
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Figure 2. The effect of TSP-1 treatment and JNK inhibitor, SP600125, 
treatment on viability in RWPE-1, PC-3, or LNCaP cells. RWPE-1 and PC-3 cells 
were plated at 20,000 cells/cm2, and LNCaP cells were plated at 40,000 cells/cm2 in tissue 
culture dishes and incubated overnight. Cells were treated with TSP-1 with or without a 
chemical inhibitor of JNK (SP600125) and incubated for 48 hours. Cells were collected by 
trypsinization, and viability was measured on a Cellometer. Data are presented as 
percentages of viable cells (viable cells / total cells) in RWPE-1 (A), PC-3 (B), and LNCaP 
(C) cells. In (B), *P-value <0.010 compared to TSP-1, 5nM; **P-value <0.044 compared 
to JNK inhibitor. In (C), *P-value <0.012 compared to TSP-1, 20nM. DMSO was the 
solvent for the JNK inhibitor. Controls were the untreated cells, TSP-1, and DMSO 
treatments. This is the result of two independent experiments. 
 
 With TSP-1 with or without Src kinase family inhibitor, PP2, treatment, no 
significant differences were observed in RWPE-1 proliferation (Figure 3A). 
Likewise, these treatments did not change proliferation in PC-3 and LNCaP cells 
(Figure 3B and 3C). As shown in Figure 4A, PP2 treatment alone decreased 
RWPE-1 cell viability as compared to the untreated group (P-value <0.02). 
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Similarly, there was a decrease in viability with the TSP-1, 20 nM, with Src 
inhibitor, PP2, as compared to TSP-1, 20 nM alone (P-value <0.001); however, 
this difference was not significantly different from PP2 treatment alone (Figure 
4A). In PC-3 cells, there was no significant change in viability with any of the 
treatments (Figure 4B). In LNCaP cells, PP2 treatment alone, and with TSP-1 
treatment, decreased viability although only the TSP-1 20 nM with PP2 treatment 
reached statistical significance as compared to TSP-1 at 20 nM alone (Figure 4C; 
P-value <0.031).  
 
 
Figure 3 TSP-1 treatment and Src family kinase inhibitor, PP2, treatment do 
not affect proliferation of RWPE-1, PC-3 or LNCaP cells. Both RWPE-1 (A) and 
PC-3 (B) were plated at 20,000 cells/cm2, and LNCaP cells (C) were plated at 40,000 
cells/cm2 in tissue culture dishes. All cells were incubated overnight. Cells were then 
treated with TSP-1 with or without a chemical inhibitor of Src family kinases (PP2) and 
incubated for 48 hours. Cells were collected by trypsinization, and total cell numbers 
were counted on a Cellometer. Data are presented as fold over the untreated control 
group. DMSO control was the equivalent volume to PP2 dose (largest volume). Controls, 
which were the untreated cells, TSP-1, and DMSO treatments, were the same controls as 
presented in Figure 1. The experiment was repeated at least twice with similar results. 
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Figure 4. The effect of TSP-1 treatment and Src family kinase inhibitor, PP2, 
treatment on viability of RWPE-1, PC-3, or LNCaP cells. RWPE-1 (A) and PC-3 
(B) cells were plated at 20,000 cells/cm2, and LNCaP cells (C) were plated at 40,000 
cells/cm2 in tissue culture dishes. All cells were incubated overnight. Cells were treated 
with TSP-1 in the presence or absence of chemical inhibitor of Src family kinases (PP2) 
and incubated for 48 hours. Cells were collected by trypsinization, and viability was 
measured on a Cellometer. Data were presented as percentages of viable cells (viable 
cells / total cells). In (A), *P-value <0.02 compared to untreated group; **P-value 
<0.001 compared to TSP-1, 20nM group. In (B), there was no significant difference 
between groups. In (C), *P-value <0.031 compared to TSP-1, 20nM. DMSO control 
was the equivalent volume to PP2 dose (largest volume). Controls, which were the 
untreated cells, TSP-1, and DMSO treatment, were the same controls as presented in 
Figure 2. This is the result of two independent studies. 
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The effects of TSP-1 with or without JNK inhibitor on PEDF protein 
levels in conditioned media (CM) and cell lysates (CL) of normal 
prostate epithelial cells or PCa cell lines 
 
 Both TSP-1 and PEDF expression are decreased in PCa tissues [25, 26]. In 
human and rat prostate tumors, decreased PEDF levels correlate with a 
metastatic phenotype [26]. Our lab has preliminary data showing that TSP-1 
treatment at 5 or 20 nM induced PEDF expression in PCa cells (Doll et al., 
unpublished data). In the present study, I asked if this TSP-1-induced PEDF 
expression was dependent on JNK or Src kinase signaling. PEDF levels were 
assessed in both CM and CL samples by ELISA. As shown in Figure 5A, TSP-1 
treatment alone did not alter secreted PEDF levels in RWPE-1 cells, while the JNK 
inhibitor, SP600125, alone significantly diminished secreted PEDF expression 
compared to untreated group (P-value <0.001). TSP-1 treatment appeared to 
modestly block SP600125‘s effect on PEDF levels. With JNK inhibitor, SP600125, 
with TSP-1 treatment, PEDF levels were decreased compared to each TSP-1 dose 
alone (P-value <0.001); however, compared to JNK inhibitor alone, PEDF levels 
were increased (Figure 5A; P-value <0.001). In this experiment, the DMSO 
control slightly increased PEDF expression compared to untreated group, and this 
increase was statistically significant (Figure 5A; P-value <0.001). In LNCaP cells, 
only the 5 nM TSP-1 treatment with JNK inhibitor, SP600125, significantly 
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decreased secreted PEDF expression as compared to TSP-1, 5 nM alone (Figure 
5B; P-value <0.009).  
 
Figure 5. The effect of TSP-1 and JNK inhibitor, SP600125, treatment on PEDF 
expression in conditioned media (CM) in RWPE-1 or LNCaP cells. RWPE-1 (A) cells 
were plated at 20,000 cells/cm2, and LNCaP cells (B) were plated at 40,000 cells/cm2 in 
tissue culture dishes. All cells were incubated overnight. Cells were then treated with TSP-1 
in the presence or absence of the JNK chemical inhibitor, SP600125, and incubated for 48 
hours. Serum-free CM was then collected and PEDF quantified by ELISA. Data are 
presented as fold over the untreated control group. In (A), *P-value <0.001 compared to 
untreated; **P-value <0.001 compared to TSP-1, 5nM; ***P-value <0.001 compared to 
TSP-1, 20nM; #P-value <0.011 compared to JNK group. In (B), *P-value <0.009 compared 
to TSP-1, 5nM group. DMSO control was the equivalent volume to PP2 dose (largest 
volume). Controls were the untreated cells, TSP-1, and DMSO treatments. For RWPE-1, the 
experiment was repeated at least twice with similar results. For LNCaP, this is the result of 
one experiment. 
 
 Intracellular PEDF expression was evaluated by ELISA in CL samples 
collected from RWPE-1 and LNCaP cells. In RWPE-1 cells, no significant changes 
were observed in the levels of PEDF protein in CL of TSP-1 treatment alone or 
the JNK inhibitor alone (Figure 6A). Interestingly, SP600125 treatment alone did 
not alter PEDF levels; however, decreased PEDF expression was observed with 5 
nM TSP-1 with SP600125 treatment as compared to JNK inhibitor alone (Figure 
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6A; P-value <0.011). In this cell line, the DMSO control moderately decreased 
PEDF expression compared to the untreated group (Figure 6A; P-value <0.013). 
In LNCaP cells, TSP-1 treatment alone did not significantly alter PEDF levels, 
although a modest decrease was observed at the 20 nM dose (Figure 6B; P-value 
<0.081). While there was a slight increase in intracellular PEDF levels with 
SP600125 alone, this was not statistically significant (Figure 6B; P-value <0.183). 
However, with SP600125 with the 5 nM TSP-1 treatment, the increase was 
statistically significant as compared to 5 nM TSP-1 treatment alone (P-value 
<0.016). 
 
Figure 6. The effect of TSP-1 and JNK inhibitor, SP600125, treatment on PEDF 
expression in cell lysate (CL) in RWPE-1 and LNCaP cells. RWPE-1 (A) cells were 
plated at 20,000 cells/cm2, and LNCaP cells (B) were plated at 40,000 cells/cm2 in tissue 
culture dishes. All cells were incubated overnight. Cells were then treated with TSP-1 with 
or without a chemical inhibitor of JNK, SP600125, and incubated for 48 hours. Cells were 
trypsinized, and cell lysate collected. Cellular PEDF levels were assessed by ELISA. Data 
were presented as fold over the untreated control group. In (A), *P-value <0.004 
compared to untreated; **P-value <0.002 compared to JNK inhibitor group. In (B), *P-
value <0.016 compared to TSP-1, 5nM. DMSO control was the equivalent volume to PP2 
dose (largest volume). Controls were the untreated cells, TSP-1, and DMSO treatments. 
Two independent studies of RWPE-1 are presented. For LNCaP, this is the result of one 
experiment. 
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The effects of TSP-1 with or without Src family kinase inhibitor on 
PEDF protein levels in conditioned media (CM) and cell lysates (CL) of 
normal prostate epithelial cells or PCa cell lines 
 
 In this study, two independent experiments on RWPE-1 cells showed 
differing results. In the first experiment, the data showed that an increase in 
secreted PEDF protein in the CM of the PP2 inhibitor alone as compared to 
untreated cells (Figure 7A; P-value <0.002). TSP-1 at 20 nM with PP2 inhibitor 
treatment significantly increased secreted PEDF levels as compared to TSP-1 at 
20 nM (P-value <0.001). Nonetheless, a decrease in secreted PEDF levels was 
detected with TSP-1 at 5 nM with PP2 treatment as compared to either 5 nM 
TSP-1 group (P-value <0.001) or PP2 inhibitor group (P-value <0.002). There 
were no effects on PEDF levels with TSP-1 treatment alone as compared to the 
untreated cells (Figure 7A; P-value <0.182). However, in a second experiment 
using RWPE-1 cells, the opposite results were obtained. The 5 nM TSP-1 
treatment significantly increased secreted PEDF levels compared to the untreated 
group (Figure 7B; P-value <0.001). However, 20 nM TSP-1 decreased 
extracellular PEDF protein levels as compared to untreated group (P-value 
<0.001). Moreover, PP2 treatment alone or with 5 or 20 nM TSP-1 significantly 
decreased PEDF levels in RWPE-1 CM as compared to related groups (Figure 7B; 
P-value <0.001). The DMSO control slightly induced PEDF levels compared to 
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untreated cells (P-value <0.001). Based on these results, additional experiments 
are needed to clarify the effect of TSP-1 on PEDF expression. 
 
 In LNCaP cells, in one experiment, the 5 nM TSP-1 treatment with PP2 
inhibitor treatment increased secreted PEDF levels as compared to 5 nM TSP-1 
alone (Figure 7C; P-value < 0.020). In addition, secreted PEDF protein levels 
were increased with PP2 inhibitor alone or with 20 nM TSP-1, yet neither was 
statistically significant. TSP-1 treatment alone in CM of LNCaP cells did not alter 
PEDF expression. This experiment needs to be repeated to confirm results.  
 
 In RWPE-1 cells, intracellular PEDF levels were not changed with TSP-1 
treatment as compared to untreated cells (Figure 8A; P-value <0.411). Similarly, 
no significant differences were observed with the 5 or 20 nM TSP-1 treatment 
with PP2 inhibitor treatment as compared to the TSP-1 at 5 or 20 nM groups and 
the PP2 group. The DMSO treatment slightly decreased PEDF protein levels in CL 
of RWPE-1 (P-value <0.004). In LNCaP cells, although increased PEDF levels 
were detected with PP2 inhibitor alone or with 5 or 20 nM TSP-1 as compared to 
related groups, no statistically significant differences were observed (Figure 8B). 
The 5 nM TSP-1 dose increased PEDF expression in CL of LNCaP cells, but it was 
not statistically significant (Figure 8B).   
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Figure 7. The effect of TSP-1 and Src kinase family inhibitor, PP2, treatment on 
PEDF expression in CM in RWPE-1 and LNCaP cells. RWPE-1 (A and B) cells were 
plated at 20,000 cells/cm2, and LNCaP cells (C) were plated at 40,000 cells/cm2 in tissue 
culture dishes. All cells were incubated overnight. Cells were then treated with TSP-1 with or 
without a chemical inhibitor of Src family kinase, PP2, and incubated for 48 hours. Serum-
free CM was then collected, concentrated and protein content quantified. PEDF levels were 
measured by ELISA. Data were presented as fold over the untreated control group. 
Significant differences were found between treatment groups. In (A and B), *P-value 
<0.001 compared to untreated; **P-value <0.001 compared to TSP-1, 5nM group; ***P-
value <0.001 compared to TSP-1, 20nM; #P-value <0.002 compared to PP2 group;<<P-
value <0.001 compared to DMSO control group. In (C), *P-value <0.020 compared to TSP-
1, 5nM. DMSO control was the equivalent volume to PP2 dose (largest volume). Controls, 
which were the untreated cells, TSP-1, and DMSO treatments, were the same as presented 
in Figure 5. Two independent studies of RWPE-1 are presented. For LNCaP, this is the result 
of one experiment. 
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Figure 8. The effect of TSP-1 and Src kinase family inhibitor, PP2, treatment on 
PEDF expression in CL in RWPE-1 and LNCaP cells. RWPE-1 (A) cells were plated at 
20,000 cells/cm2, and LNCaP cells (B) were plated at 40,000 cells/cm2 in tissue culture 
dishes. All cells were incubated overnight. Cells were then treated with TSP-1 in the 
presence or absence of Src family kinase inhibitor, PP2, and incubated for 48 hours. Cells 
were trypsinized, and cell lysates were collected and the total protein content quantified. 
PEDF levels were assessed by ELISA. Data are presented as fold over the untreated control 
group. In (A), *P-value <0.004 compared to untreated. DMSO control was the equivalent 
volume to PP2 dose (largest volume). Controls, which were the untreated cells, TSP-1, and 
DMSO treatments, were the same as presented in Figure 6. Two independent studies of 
RWPE-1 are presented. For LNCaP, this is the result of one experiment. 
 
 To visualize the PEDF in the CL samples and to confirm the molecular 
weight of the PEDF, Western blot assays were performed on LNCaP and PC-3 CL 
samples. As depicted in Figure 9, PEDF expression was detected in untreated 
samples and experimental samples. Membranes were stripped and re-probed 
with GAPDH as a control for equal protein loading (Figure 9).. PEDF protein 
levels in the CL of LNCaP cells treated with SP600125 inhibitor alone or with 5 or 
20 nM TSP-1 increased in ELISA while decreased PEDF expression was observed 
in Western blot assay. No differences were observed with PP2 inhibitor alone or 
with 5 or 20 nM TSP-1 in these assays. Intracellular PEDF expression in PC-3 cell 
39  
 
lines was also detected. As shown in Figure 10, PEDF expression was detected in 
untreated samples, TSP-1 treatment alone samples, and DMSO treatment 
samples. In addition, PEDF expression was identified in TSP-1 in the presence of 
SP600125 or PP2 samples. GAPDH was used as a control for equal protein 
loading.  
 
 
 
 
Figure 9. The effect of TSP-1 and JNK or Src family kinase inhibitor treatment on 
PEDF expression in CL samples in LNCaP cells. LNCaP cells were plated at 40,000 
cells/cm2 in tissue culture dishes and were incubated overnight. Cells were treated with TSP-1  
with or without specific JNK inhibitor (SP600125) or a Src family kinase inhibitor (PP2). CL 
samples were separated on SDS-PAGE gels (12%). The separated proteins were transferred 
to PVDF membrane by electroblotting. Membranes were probed with anti-PEDF antibody, 
stripped and reprobed with GAPDH antibody, which served as a control for protein loading. 
Lanes are as follows: 1, Untreated sample; 2, 5 nM TSP-1; 3, 20 nM TSP-1; 4, 20 μM JNK 
inhibitor; 5, 5 nM TSP-1 + 20 µM JNK inhibitor; 6, 20 nM TSP-1 + 20 µM JNK inhibitor; 7, 20 
µM Src inhibitor; 8, 5 nM TSP-1 + 20 µM Src inhibitor; 9, 20 nM TSP-1 + 20 µM Src inhibitor; 
10, DMSO control.  
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Figure 10. The effect of TSP-1 and JNK or Src family kinase inhibitor treatment on 
PEDF expression in CL samples in PC-3 cells. PC-3 cells were plated at 20,000 cells/cm2 
in tissue culture dishes and were incubated overnight. Cells were treated with TSP-1 with or 
without a specific JNK inhibitor (SP600125) or a Src family kinase inhibitor (PP2). CL samples 
were separated on SDS-PAGE gels (12%). The separated proteins were transferred to PVDF 
membrane by electroblotting. Membranes were probed with anti-PEDF antibody, stripped 
and reprobed with GAPDH antibody, which served as a control for protein loading. Lanes are 
as follows: 1, Untreated sample; 2, 5 nM TSP-1; 3, 20 nM TSP-1; 4, 20 μM JNK inhibitor; 5, 
5 nM TSP-1 + 20 µM JNK inhibitor; 6, 20 nM TSP-1 + 20 µM JNK inhibitor; 7, 20 µM Src 
inhibitor; 8, 5 nM TSP-1 + 20 µM Src inhibitor; 9, 20 nM TSP-1 + 20 µM Src inhibitor; 10, 
DMSO control.  
 
 
The effect of TSP-1 with or without JNK inhibitor on the lipolytic 
activity of normal prostate epithelial cells and PCa cells 
 
 Preliminary studies suggest that TSP-1 treatment plays a role in PCa cell 
lipid metabolism (Doll et al., unpublished data). Previous work has also shown 
that PEDF regulates lipid metabolism in PCa cells (Doll et al., unpublished data). 
Therefore, the potential alteration of lipolytic activity in the CM of RWPE-1, 
LNCaP, and PC-3 cells treated with 5 or 20 nM TSP-1 with or without SP600125 
or PP2 inhibitor treatment was evaluated by a quantification of secreted glycerol.  
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 In RWPE-1 cell lines, the 5 nM TSP-1 treatment increased lipolytic activity 
compared to untreated cells (P-value <0.015) while there was no statistically 
significant difference in lipolysis with 20 nM TSP-1 (Figure 11A). However, 
SP600125 treatment alone decreased lipolytic activity, but this was not 
statistically significant in comparison to untreated group (Figure 11A; P-value 
<0.098). A significant decrease in lipolytic activity of RWPE-1 was detected with 
the 5 nM TSP-1 with SP600125 inhibitor treatment as compared to TSP-1 at 5nM 
(Figure 11A; P-value <0.023). Similarly, 20 nM TSP-1 in the presence of JNK 
inhibitor significantly reduced lipolysis compared to 20 nM TSP-1 (P-value 
<0.027). As shown in Figure 11B, 5 nM TSP-1 treatment increased lipolytic 
activity of PC-3 cells, but this increase was not a statistically significant 
difference. However, a significant decrease in lipolysis was observed with TSP-1 
at 5nM treatment with SP600125 inhibitor treatment as compared to TSP-1, 5nM 
(Figure 11B; P-value <0.010).  
 
 In LNCaP cells, in two combined independent experiments, the 5 or 20 nM 
TSP-1 treatment alone reduced liplolysis, yet this reduction was not statistically 
significant (Figure 11C). However, an increase in lipolytic activity in LNCaP was 
observed with SP600125 inhibitor treatment alone, or with the 5 or 20 nM TSP-1, 
treatment, but again was not significantly different (Figure 11C). In a second 
independent experiment with LNCaP cells, the results showed that lipolysis was 
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induced with the 5 or 20 nM TSP-1 treatment, but no significant differences in 
lipolysis were observed in contrast to the untreated group (Figure 11D). 
Furthermore, SP600125 inhibitor treatment alone decreased lipolytic activity 
compared to the untreated group (Figure 11D; P <0.001). Interestingly, 
increased lipolytic activity was detected with 5 or 20 nM TSP-1 treatment with 
JNK inhibitor as compared to the JNK inhibitor group (Figure 11D; P-value 
<0.001). The DMSO control significantly decreased lipolytic activity compared to 
untreated group (Figure 11D; P-value <0.001).  
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Figure 11. The effect of TSP-1 with a chemical inhibitor of JNK kinase on lipolytic 
activity in RWPE-1, PC-3 and LNCaP cells. Both RWPE-1 (A) and PC-3 (B) were plated 
at 20,000 cells/cm2, and LNCaP cells (C and D) were plated at 40,000 cells/cm2 in tissue 
culture dishes. All cells were incubated overnight. Cells were then treated with TSP-1 with or 
without chemical inhibitor of signaling mediator JNK, SP600125, and incubated for 48 hours. 
Serum-free conditioned media was then collected and lipolytic activity quantified using the 
free glycerol assay. Data were normalized to total cell count and compared as fold over 
values. In (A), *P-value <0.015 compared to untreated group; **P-value <0.023 compared 
to TSP-1, 5nM group; ***P-value <0.027 compared to TSP-1, 20nM group. In (B), P-value 
<0.010 compared to TSP-1, 5nM. No statistical differences were found in (C) cells. In (D), 
*P-value <0.001 compared to untreated group; **P-value <0.001 compared to TSP-1, 5nM 
group; ***P-value <0.001 compared to TSP-1, 20nM group; #P-value <0.001 compared to 
JNK inhibitor group. DMSO control was an equivalent volume to PP2 dose (largest volume). 
Controls were the untreated cells, TSP-1 treatment, and DMSO treatment. This is the result of 
two independent experiments with similar in results for A and B. For C and D are the result of 
two independent experiments. 
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The effect of TSP-1 with or without Src family kinase inhibitor on the 
lipolytic activity of normal prostate epithelial cells and PCa cells 
 
 In RWPE-1 cells, lipolytic activity was significantly decreased with PP2 
inhibitor treatment alone as compared to the untreated group (Figure 12A; P-
value <0.021). Likewise, 5 nM TSP-1 with PP2 inhibitor treatment decreased 
lipolytic activity compared to the 5 nM TSP-1 group (P-value <0.008). In 
addition, as shown in Figure 12A, the TSP-1 at 20 nM treatment with PP2 
inhibitor significantly decreased lipolysis of RWPE-1 cells as compared to TSP-1, 
20nM (P-value <0.018). In PC-3 cells, lipolytic activity was not altered with the 5 
nM TSP-1 treatment alone (Figure 12B). TSP-1 at the 20 nM dose decreased 
lipolysis, but this was not significantly different as compared to the untreated 
group (Figure 12B). In addition, with PP2 inhibitor treatment alone, a significant 
decrease of lipolysis was observed as compared to the untreated group (P-value 
<0.021). Compared to the 20 nM TSP-1 treatment alone, the TSP-1 at 20 nM 
treatment with PP2 inhibitor treatment decreased lipolytic activity (P-value 
<0.029). However, the 5 nM TSP-1 with Src family kinase inhibitor treatment did 
not affect lipolysis levels in PC-3 cells. 
 
 In LNCaP cells, the 5 or 20 nM TSP-1 treatment alone decreased lipolysis; 
yet, these changes were not statistically significant (Figure 12C). With PP2 
inhibitor treatment alone, an increase in lipolysis was observed in LNCaP cells. 
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Likewise, TSP-1 at the 5 or 20 nM in the presence of PP2 inhibitor treatment 
induced lipolysis (Figure 12C). No statistically significant difference was observed 
in this study as compared to related groups (Figure 12C). A second, independent 
experiment on LNCaP cells, however, showed contrary results. In this 
experiment, TSP-1 treatment at the 5 or 20 nM increased lipolytic activity, but 
this was not statistically different (Figure 12D). However, PP2 treatment 
significantly decreased lipolysis of LNCaP as shown in Figure 12D (P-value 
<0.001). As presented in Figure 12D, the 5 nM TSP-1 treatment with PP2 
inhibitor treatment significantly decreased lipolytic activity in LNCaP cells as 
compared to the 5 nM TSP-1 group (P-value <0.001) and the Src inhibitor group 
(P-value <0.001). Similar data were obtained with the 20 nM TSP-1 with PP2 
inhibitor treatment as compared to the TSP-1 at 20nM group (P-value <0.001) 
and the Src inhibitor group (P-value <0.001). The DMSO control significantly 
decreased lipolytic activity of LNCaP cells compared to untreated group (Figure 
12D; P-value <0.001).  
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Figure 12. The effect of TSP-1 with chemical inhibitor of Src family kinase on 
lipolytic activity in RWPE-1, PC-3 and LNCaP cells. Both RWPE-1 (A) and PC-3 (B) 
were plated at 20,000 cells/cm2, and LNCaP cells (C and D) were plated at 40,000 cells/cm2 
in tissue culture dishes. All cells were incubated overnight. Cells were then treated with TSP-
1 with or without chemical inhibitor of Src family kinase, PP2, and incubated for 48 hours. 
Serum-free conditioned media was then collected and lipolytic activity quantified using the 
free glycerol assay. Data were normalized to total cell count and compared as fold over 
values. There were significant differences between groups. In (A), *P-value <0.021 
compared to untreated group; **P-value <0.008 compared to TSP-1, 5nM group; ***P-
value <0.018 compared to TSP-1, 20nM group. In (B), *P-value <0.021 compared to 
untreated group; **P-value <0.029 compared to TSP-1, 20nM. No statistical differences 
were found in (C) cells. In (D), *P-value <0.001 compared to untreated group; **P-value 
<0.001 compared to TSP-1, 5nM group; ***P-value <0.001 compared to TSP-1, 20nM 
group; #P-value <0.001 compared to JNK inhibitor group. DMSO control was an equivalent 
volume to PP2 dose (largest volume). Controls, which were the untreated cells, TSP-1 
treatment, and DMSO treatment, were the same as shown in Figure 11. This is the result of 
two independent experiments with similar results for A and B. For C and D are the result of 
two independent experiments. 
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 DISCUSSION 
 
 TSP-1 has been identified as a functional inhibitor of angiogenesis 
secreted by prostate epithelial cells [26]. The decreased level of TSP-1 in PCa, 
combined with the increased level of angiogenesis inducers, such as VEGF and 
fibroblast growth factor in PCa tissue [26], creates a pro-angiogenic 
environment. PEDF levels have also been shown to be decreased in PCa tissues 
[25]. In other tissue types, some studies have reported a link between TSP-1 
and PEDF. For example, one study showed a positive association between 
expression levels of TSP-1 and PEDF in the vitreous fluid of diabetic patients 
[84]. Another study revealed that in pancreatic cells, PEDF overexpression 
inhibited TSP-1 levels [85]. The relationship between TSP-1 and PEDF in prostate 
tissues has not been well studied. A few recent studies in prostate cells; 
however, have shown that TSP-1 induces PEDF expression and lipolytic activity 
(Doll et al., unpublished data).  
 
 The molecular pathways through which TSP-1 signals in prostate cells is 
currently unexplored. In endothelial cells, where TSP-1 signaling has been well 
studied, the anti-angiogenic activity of TSP-1 is mediated through the 
intracellular signaling molecules, JNK and Fyn kinases [54]. JNK inhibition 
decreased endothelial cell proliferation and migration in vitro [65]. Furthermore, 
TSP-1 is unable to inhibit corneal angiogenesis in Fyn null mice or in wild type 
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mice in the presence of inhibitors that block the activity of p38 [66]. The 
question addressed in this study was whether or not TSP-1- induced PEDF 
expression and/or lipolytic activity was dependent on induction of JNK and/or Src 
family kinase signaling in RWPE-1 normal prostate epithelial cells and in the PCa 
cell lines, LNCaP and PC-3.  
 
 In this study, TSP-1 treatment did not alter the proliferation or viability of 
RWPE-1 cells. In a previous study, neither TSP-1 treatment at 5 nM nor 20 nM 
changed the proliferation or viability of RWPE-1 cells (Doll et al., unpublished 
data). RWPE-1 cells did not show significant changes in proliferation rate or in 
viability when exposed to the JNK inhibitor treatment, alone or with co-treatment 
with TSP-1. Similarly, proliferation of RWPE-1 was not altered with the Src family 
kinase inhibitor alone or with TSP-1. However, viability was reduced with with 
the Src family kinase inhibitor alone or with the Src family kinase inhibitor with 
the 20 nM TSP-1 treatment. Together, these data support that TSP-1, JNK, or 
Src family kinase signaling pathways are not required for RWPE-1 proliferation.  
 
 PEDF is down-regulated in PCa, where its loss has been linked to a 
metastatic phenotype [30]. In human malignant U251 glioma cells, an increase 
in PEDF expression stimulates TSP-1 expression [61]. Another study showed that 
PEDF expression increased TSP-1 levels in KM12 colon cancer cells, which led to 
decreased microvessel density [62]. In the present study, secreted PEDF levels in 
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RWPE-1 cells were not significantly altered with TSP-1 treatment alone. In two 
previous experiments in the our lab, inconsistent results were obtained. The first 
experiment showed that PEDF levels were significantly increased with 5 or 20 nM 
TSP-1 (Doll et al., unpublished data); however, in the second experiment, 
secreted PEDF levels were not affected by 5 or 20 nM TSP-1 treatment, and my 
data is consistent with this second observation. One likely explanation for the 
differences that I observed in response to TSP-1 treatment between these 
experiments is that the difference lots of TSP-1 were used. It is well known that 
TSP-1 is a large, 450-kDa glycoprotein, having several domains interacting with 
numerous cell receptors and proteases involved in angiogenesis [86]. TSP-1 can 
have different activity through protein interactions. However, when a specific 
domain of TSP-1 is cleaved, the remaining anti-angiogenic domains have been 
shown to have decreased anti-angiogenic activity [87]. Thus, the lot of TSP-1 
and/or TSP-1 degradation could have been a factor. 
 
 Interestingly, secreted PEDF levels were reduced with JNK inhibition alone 
in RWPE-1 cells. This suggests that JNK signaling plays a significant role in the 
regulation of PEDF expression in RWPE-1 cells. The TSP-1 treatment modestly 
suppressed the JNK-inhibitor-mediated decrease in PEDF levels, but these levels 
were still significantly decreased compared to TSP-1 treatment alone. Thus, both 
TSP-1 and JNK molecule seem to function in the regulation of secreted PEDF 
levels in RWPE-1 cells. However, these results have to be viewed with some 
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caution, as the DMSO control showed an increase in PEDF levels in CM of RWPE-
1 cells, and this increase was significantly different compared to untreated cells. 
Consequently, it is necessary to examine if DMSO treatment affects PEDF levels 
in RWPE-1 cells. Data obtained on secreted PEDF of RWPE-1 cells produced 
somewhat differing results with PP2 treatment alone or with TSP-1 at 5 or 20 nM 
treatment in two independent experiments. Further investigations are necessary 
to confirm these effects. 
 
 PEDF has been intensively studied as a secreted protein, while more 
recently, it has been studied for its intracellular functions. Intracellular PEDF has 
been detected in both the cytoplasm and nucleus in several cell types, including 
retinal pigment epithelial, retinoblastoma, neuroblastoma, and hepatocarcinoma 
cells [88, 89]. In these experiments, intracellular PEDF in RWPE-1 cells was not 
significantly changed with TSP-1 treatment. In previous studies, two independent 
experiments showed different results. In the first of these, 5 or 20 nM TSP-1 
treatment did not alter PEDF expression in RWPE-1 CL (Doll et al., unpublished 
data). However, in the second previous experiment, treatment with 5 or 20 nM 
TSP-1 decreased PEDF levels compared to untreated cells (Doll et al., 
unpublished data). My data were consistent with the first experiment; however, 
the experiment should be repeated at least one more time to confirm these 
results.  
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 JNK inhibition alone or in combination with TSP-1 at 20 nM did not altere 
intracellular PEDF levels in RWPE-1 cells, while TSP-1 at 5 nM with JNK inhibition 
significantly decreased PEDF. The DMSO control decreased PEDF expression, but 
no significant differences were observed between the DMSO control and the TSP-
1 at 5 nM with JNK inhibitor treatment; therefore, TSP-1 could regulate PEDF 
expression through JNK pathway in RWPE-1. With Src family kinase inhibition or 
in combination with TSP-1 treatment, no change in expression levels of PEDF 
was observed in the RWPE-1 CL. These observations suggested that Src family 
kinases do not play a role in the regulation of intracellular PEDF expression in 
RWPE-1 cells. 
 
 Dysregulation in lipid metabolism is an established hallmark of cancer. Dai 
et al. showed that intracellular PEDF interacts with and facilitates ATGL 
translocation onto cellular lipid droplets, which then induces triglyceride 
degradation in hepatocytes [90]. In addition, knockdown of endogenous PEDF in 
liver cells decreased triglyceride degradation [90]. It has been proposed that 
PEDF also plays a role in lipid metabolism in PCa (Doll et al., unpublished data). 
In the present study, data obtained from RWPE-1 cells treated with 5 nM TSP-1 
showed an increase in lipolysis. These data were consistent with the previous 
work (Doll et al., unpublished data). JNK inhibition alone or JNK inhibition with 
the 5 or 20 nM TSP-1 treatment significantly reduced lipolytic activity in RWPE-1 
cells. Likewise, a reduction in lipolytic activity was identified with inhibition of the 
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Src family kinases, alone or in combination with TSP-1. These results indicated 
that TSP-1- induced lipolytic activity is dependent on JNK activation and/or Src 
family kinase activation in RWPE-1. 
 
 In this study, neither the 5 nor the 20 nM TSP-1 treatment affected PC-3 
cell proliferation. However, in a previous study, the TSP-1 at the 5 nM treatment 
increased proliferation of PC-3 cells (Doll et al., unpublished data); therefore, a 
repeat experiment should be performed to clarify this discrepancy. The viability 
of PC-3 cells was not altered with TSP-1 treatment in the present study, which is 
consistent with the previous study in the lab (Doll et al., unpublished data). PC-3 
cell proliferation was not altered with JNK inhibition alone or in combination with 
TSP-1. Interestingly, the 5 nM TSP-1 with JNK inhibition treatment slightly 
increased the viability of PC-3 cells, which suggests that TSP-1 treatment in the 
presence of JNK inhibition plays a role in PC-3 cell viability. Neither the Src family 
kinase inhibition alone nor in combination with TSP-1 altered the proliferation or 
the viability of PC-3 cells.  
 
 With respect to lipolytic activity, while TSP-1 treatment at the 5 nM dose 
slightly increased lipolysis in PC-3 cells, decreased activity was observed with the 
20 nM TSP-1 dose. However, neither change was statistically significant 
compared to untreated cells. In a previous study, 20 nM TSP-1 treatment 
significantly increased lipolytic activity, whereas 5 nM TSP-1 slightly decreased 
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lipolytic activity in the PC-3 cells (Doll et al., unpublished data). This inconsistent 
data between studies may be due to differences in the activity of TSP-1 between 
lots of protein, as discussed above. These findings suggest that future studies 
should analyze the effect of TSP-1 on lipolytic activity in PC-3 to determine if a 
true difference exists. The JNK inhibitor treatment alone or in combination with 
TSP-1 treatment decreased lipolytic activity of PC-3 cells. Inhibition of the Src 
family kinases alone or in combination with 5 or 20 nM TSP-1 treatment also 
resulted in a reduction in lipolytic activity. Since these results are from two 
independent experiments, these studies would support that lipolytic activity in 
PC-3 cells is, in part, regulated by JNK and/or Src family kinase activity.  
 
 LNCaP proliferation was not altered with TSP-1 treatment; however, in a 
previous study, TSP-1 treatment increased LNCaP proliferation (Doll et al., 
unpublished data). This inconsistency could also be due to the fact that different 
lots of TSP-1 protein were used between my and the previous study. In LNCaP 
cells, there was no statistically significant decrease of viability observed with 
TSP-1 treatment. This observation is consistent with the prior investigation (Doll 
et al., unpublished data). The JNK inhibition alone or with TSP-1 treatment had 
no effect on LNCaP cell proliferation. In addition, TSP-1 at 20 nM with JNK 
inhibition decreased viability in LNCaP cells. The Src family kinase inhibition alone 
or with TSP-1 treatment did not alter LNCaP cell proliferation. In contrast, a 
reduction in LNCaP cell viability was observed with the Src family kinase 
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inhibition alone or in combination with 5 nM TSP-1, but these results were not 
statistically significant. However, a statistically significant decrease in LNCaP 
viability was observed with 5 nM TSP-1 with Src family kinase inhibition. A study 
reported that inhibition of Src family kinase activation decreased LNCaP growth 
[91]. In addition, in pancreatic cancer cells, proliferation was suppressed with Src 
inhibitors [92]. My data are consistent with these studies. Thus, these data 
suggest that Src family kinases play a role in the viability in LNCaP cells and that 
may modify its effect. 
 
 TSP-1 at 5 nM treatment increased secreted PEDF levels, while the 20 nM 
TSP-1 treatment decreased PEDF levels, in LNCaP cells. However, neither dose 
was statistically significant compared to untreated cells. The increased PEDF with 
5 nM TSP-1 treatment is consistent with a previous study in the lab (Doll et al., 
unpublished data); however, the 20 nM TSP-1 treatment was inconsistent with 
previous data, which showed an increase in secreted PEDF levels. As previously 
stated, the differences in results could be due to a degradation of TSP-1 and/or 
difference in lot activity. Based on the variation of PEDF levels observed in these 
two studies, further experiments are necessary to clarify if TSP-1 does induce 
PEDF expression in LNCaP cells.  
 
 JNK inhibition decreased secreted PEDF protein levels from LNCaP cells, but 
this result was not statistically significant. However, TSP-1 at 5 nM with JNK 
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inhibition significantly reduced secreted PEDF. These findings suggest that JNK 
play a role in the regulation of secreted PEDF in LNCaP cells and that TSP-1 may 
modify its effect. Surprisingly, the Src family kinase inhibition alone or in 
combination with 5 or 20 nM TSP-1 elevated secreted PEDF levels. These results 
indicated that the Src family kinases play an important role in suppressing 
secreted PEDF levels. Together, the mechanism linking PEDF expression and JNK 
or Src family kianse remains unclear in LNCaP cells; therefore, further 
investigations are required to confirm the effects of TSP-1 with JNK or Src family 
kinase inhibition on secreted PEDF expression in LNCaP cells.  
 
 In LNCaP CL collected from cells treated with 5 nM TSP-1, a small increase 
in PEDF levels was observed, while with 20 nM TSP-1 treatment, there was a 
slight decrease in PEDF expression. A previous study in our lab showed that both 
doses of TSP-1 (5 or 20 nM) increased intracellular PEDF levels; thus, my data at 
the 20 nM dose is inconsistent with this previous study. The differences in the 
results between my data and the previous data could be due to several factors. 
In the prior study, the LNCaP cells were plated at 20,000 cells/cm2, whereas I 
plated the LNCaP cells at 40,000 cells/cm2. Therefore, the cell density might 
affect how the cells respond to TSP-1 doses as well as the lots and activity levels 
of TSP-1 used. 
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 In LNCaP cells, the JNK inhibition treatment alone or with TSP-1 at 20 nM 
dose increased intracellular PEDF protein levels; however, no statistical 
differences were observed among groups. PEDF levels were significantly 
increased with 5 nM TSP-1 treatment in the presence of the JNK inhibitor 
treatment. This result indicates that the JNK pathway did not mediated the TSP-
1-induced intracellular PEDF in LNCaP cells. The Src family kinase inhibition 
treatment, alone or with TSP-1, increased intracellular PEDF levels in LNCaP 
cells. In reported study, the authors showed that LNCaP cells overexpressed Src 
family kinases [93]. In the present study, inhibition of Src family kinase activity 
elevated both secreted and intracellular PEDF levels in LNCaP cells. Together, 
these data suggest that increased Src activity in LNCaP cells down-regulates 
PEDF expression. To determine if Fyn specifically, or other Src family kinase 
members, mediates TSP-1 induced intra- or extracellular PEDF expression in 
LNCaP cells, further investigations using a specific inhibitor, if available, or siRNA 
technologies, are necessary.  
 
 Lipolytic activity was measured in three independent studies of LNCaP cells, 
and conflicting results were obtained in each experiment. One of these 
experiments was consistent with a previous study, which showed an increase in 
lipolytic activity with TSP-1 treatment. The JNK inhibition treatment, alone or in 
combination with TSP-1 treatment, showed inconsistent effect on lipolytic activity 
in LNCaP cells. Likewise, conflicting data were also observed with Src family 
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kinase inhibition alone or with TSP-1 treatment. Even though these data were 
inconsistent, it seems possible that TSP-1, JNK and/or Src kinase signaling play a 
significant role in the regulation of lipolysis in LNCaP cells. However, further 
studies are required before firm conclusions can be made. 
 
 While some studies report that an absence of TSP-1 expression is 
correlated with a poor prognosis in PCa, in this study, TSP-1 did not inhibit PCa 
cell proliferation in vitro [94]. Similar to my data, a study proposed that there 
was no correlation between TSP-1 expression and cancer cell proliferation in 
renal cell carcinoma tissues [95]. Likewise, cell proliferation in breast cancer cells 
was not altered with TSP-1 expression [96]. However, a study reported that TSP-
1 expression suppressed proliferation of small cell lung carcinoma [97]. 
Therefore, the importance of TSP-1 seems to vary and shows different effects on 
different types of cells or tissues. 
 
  I observed that inhibition of JNK activity led to reduced extracellular PEDF 
levels in RWPE-1 and LNCaP cells. JNK deficiency reduced tumor development in 
prostate [98], lymphoma [99], and lung cancer models [100]. I found that JNK 
activation suppressed expression of PEDF, a potent tumor suppressor in PCa. In 
the present study, JNK and/or Src family kinase inhibition alone or with TSP-1 
inhibited lipolytic activity in RWPE-1 and PC-3 cells. Consistent with these data, it 
has been reported that the JNK pathway could play a role in the regulation of 
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lipolysis in mouse adipocytes [101]. Another group investigated Src activity in 
mouse 3T3-L1 preadipocytes and found that blocking Src family kinases, using 
either PP2 or siRNA inhibited lipolysis [102].  
 
 One explanation for the differences in response to treatment that I 
observed in my study between cell lines is that the genetic background of the 
cells. While PC-3 is an androgen-insensitive cell line, LNCaP cells are androgen-
sensitive. In addition, PC-3 is derived from bone marrow whereas LNCaP cells 
are derived from lymph node [81, 82]. For example, PTEN gene plays a role in 
cellular senescence, and the three cell lines show different patterns of expression 
in this gene. A study found that JNK activity was increased in PTEN null cells 
[103]. Therefore, differential response of PC-3 and LNCaP cells to TSP-1 with 
either JNK or Src family kinase inhibitor treatments may be due to some defects 
in the signaling pathways. 
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CONCLUSION 
 
 To my knowledge, this is the first study investigating if TSP-1 activity is 
regulated via either JNK or Src family kinase signaling pathways. My data clearly 
demonstrates that TSP-1, JNK and/or Src family kinases could regulate anti-
tumor activity in PCa cells. The central hypothesis of this study was that TSP-1- 
induced PEDF expression and/or lipolytic activity was dependent on induction of 
JNK and/or Fyn signaling in RWPE-1 normal prostate epithelial cells and in the 
PCa cell lines, LNCaP and PC-3. I investigated proliferation, viability, PEDF levels, 
and lipolytic activity in vitro. Viability was slightly altered with the TSP-1 
treatment with the JNK inhibitor treatment or the Src family kinase inhibitor 
treatment in RWEP-1, PC-3 and LNCaP cells. In RWPE-1 and LNCaP cells, 
secreted PEDF levels were decreased with the JNK inhabitation, alone or with 
TSP-1 treatment. However, TSP-1 treatment in the presence of the Src family 
kinase inhibition increased secreted PEDF levels in LNCaP cells. Similarly, 
intracellular PEDF expression was elevated by TSP-1 with PP2 inhibitor treatment 
in LNCaP cells. Lipolytic activity was significantly suppressed by TSP-1 treatment 
with JNK or Src family kinase inhibition in RWPE-1 and PC-3. In this study, TSP-1 
did not induce PEDF expression and/or lipolytic activity in PCa cells. However, I 
found that the activation of JNK and/or Src family kinases might be a significant 
regulator in induction of PEDF expression in RWEP-1 and LNCaP cells. In 
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addition, the activity of JNK or Src family kinases could regulate lipolytic activity 
in RWPE-1 and PC-3. Since Src family kinases are composed of several members 
[104], and PP2 is not a Fyn-specific inhibitor, future experiments, using an siRNA 
approach would be necessary to specifically test if Fyn, or other Src family kinase 
members, are required for this activity.  
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